These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 21310254)

  • 1. Serious infection risk and immune recovery after double-unit cord blood transplantation without antithymocyte globulin.
    Sauter C; Abboud M; Jia X; Heller G; Gonzales AM; Lubin M; Hawke R; Perales MA; van den Brink MR; Giralt S; Papanicolaou G; Scaradavou A; Small TN; Barker JN
    Biol Blood Marrow Transplant; 2011 Oct; 17(10):1460-71. PubMed ID: 21310254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of conditioning regimens with or without antithymocyte globulin for unrelated cord blood transplantation in children with high-risk or advanced hematological malignancies.
    Zheng C; Luan Z; Fang J; Sun X; Chen J; Li CK; Hu S; Zhu Y; Sun Z
    Biol Blood Marrow Transplant; 2015 Apr; 21(4):707-12. PubMed ID: 25598277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies.
    Xuan L; Huang F; Fan Z; Zhou H; Zhang X; Yu G; Zhang Y; Liu C; Sun J; Liu Q
    J Hematol Oncol; 2012 Aug; 5():46. PubMed ID: 22856463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies.
    Law AD; Salas MQ; Lam W; Michelis FV; Thyagu S; Kim DDH; Lipton JH; Kumar R; Messner H; Viswabandya A
    Biol Blood Marrow Transplant; 2018 Nov; 24(11):2259-2264. PubMed ID: 30009980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose individualized antithymocyte globulin with therapeutic drug monitoring in high-risk cord blood transplant.
    Admiraal R; Versluijs AB; Huitema ADR; Ebskamp L; Lacna A; de Kanter CTK; Bierings MB; Boelens JJ; Lindemans CA; Nierkens S
    Cytotherapy; 2024 Jun; 26(6):599-605. PubMed ID: 38466262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted dosing of anti-thymocyte globulin in adult unmanipulated haploidentical peripheral blood stem cell transplantation: A single-arm, phase 2 trial.
    Wang H; Wang N; Wang L; Du J; Li F; Shao Y; Peng B; Luan S; Wang L; Jin X; Gao C; Dou L; Liu D
    Am J Hematol; 2023 Nov; 98(11):1732-1741. PubMed ID: 37706580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HLA 1-3 antigen-mismatched related peripheral blood stem cells transplantation using low-dose antithymocyte globulin versus unrelated cord blood transplantation.
    Wada F; Watanabe M; Konuma T; Okabe M; Kobayashi S; Uchida N; Ikegame K; Tanaka M; Sugio Y; Mukae J; Onizuka M; Kawakita T; Kuriyama T; Takahashi S; Fukuda T; Nakano N; Sawa M; Kimura T; Ichinohe T; Atsuta Y; Kanda J;
    Am J Hematol; 2022 Mar; 97(3):311-321. PubMed ID: 34978726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of ATG-thymoglobulin with ATG-Fresenius for Epstein-Barr virus infections and graft-versus-host-disease in patients with hematological malignances after haploidentical hematopoietic stem cell transplantation: a single-center experience.
    Zhou L; Gao ZY; Lu DP
    Ann Hematol; 2020 Jun; 99(6):1389-1400. PubMed ID: 32291495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal Active Anti-Thymocyte Globulin Exposure Associated with Minimum Risk of Virus Reactivation and Comparable Acute Graft-Versus-Host Disease Under Adult Myeloablative Haploidentical Peripheral Blood Stem Cell Transplantation.
    Wang H; Zhao Y; Fang S; Wang L; Peng B; Yang J; Wang N; Du J; Li F; Jin X; Luan S; Wu X; Dou L; Liu D
    Transplant Cell Ther; 2022 Jun; 28(6):332.e1-332.e10. PubMed ID: 35314377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two dose levels of rabbit antithymocyte globulin as graft-versus-host disease prophylaxis in haploidentical stem cell transplantation: a multicenter randomized study.
    Lin R; Wang Y; Huang F; Fan Z; Zhang S; Yang T; Xu Y; Xu N; Xuan L; Ye J; Sun J; Huang X; Liu Q
    BMC Med; 2019 Aug; 17(1):156. PubMed ID: 31401973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. General and Virus-Specific Immune Cell Reconstitution after Double Cord Blood Transplantation.
    Saliba RM; Rezvani K; Leen A; Jorgensen J; Shah N; Hosing C; Parmar S; Oran B; Olson A; Rondon G; Chen J; Martinez C; Hamdi A; Mehta RS; Chemaly RF; Saunders IM; Bollard CM; Shpall EJ
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1284-90. PubMed ID: 25708219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies.
    Hamadani M; Blum W; Phillips G; Elder P; Andritsos L; Hofmeister C; O'Donnell L; Klisovic R; Penza S; Garzon R; Krugh D; Lin T; Bechtel T; Benson DM; Byrd JC; Marcucci G; Devine SM
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1422-30. PubMed ID: 19822302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
    Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of rabbit ATG-containing myeloablative conditioning regimens on the outcome of patients undergoing unrelated single-unit cord blood transplantation for hematological malignancies.
    Pascal L; Mohty M; Ruggeri A; Tucunduva L; Milpied N; Chevallier P; Tabrizi R; Labalette M; Gluckman E; Labopin M; Yakoub-Agha I
    Bone Marrow Transplant; 2015 Jan; 50(1):45-50. PubMed ID: 25330221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
    Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
    Ann Hematol; 2019 Sep; 98(9):2163-2177. PubMed ID: 31243569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double umbilical cord blood transplantation in patients with hematologic malignancies using a reduced-intensity preparative regimen without antithymocyte globulin.
    Ostronoff F; Milano F; Gooley T; Gutman JA; McSweeney P; Petersen FB; Sandmaier BM; Storb R; Delaney C
    Bone Marrow Transplant; 2013 Jun; 48(6):782-6. PubMed ID: 23241738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequent human herpesvirus-6 viremia but low incidence of encephalitis in double-unit cord blood recipients transplanted without antithymocyte globulin.
    Olson AL; Dahi PB; Zheng J; Devlin SM; Lubin M; Gonzales AM; Giralt SA; Perales MA; Papadopoulos EB; Ponce DM; Young JW; Kernan NA; Scaradavou A; O'Reilly RJ; Small TN; Papanicolaou G; Barker JN
    Biol Blood Marrow Transplant; 2014 Jun; 20(6):787-93. PubMed ID: 24548875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence, risk factors, and outcome of cytomegalovirus viremia and gastroenteritis in patients with gastrointestinal graft-versus-host disease.
    Bhutani D; Dyson G; Manasa R; Deol A; Ratanatharathorn V; Ayash L; Abidi M; Lum LG; Al-Kadhimi Z; Uberti JP
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):159-64. PubMed ID: 25445637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Low-dose Anti-thymocyte Globulin as Standard Prophylaxis in Mismatched and Matched Unrelated Hematopoietic Peripheral Stem Cell Transplantation for Hematologic Malignancies.
    Sakellari I; Batsis I; Bousiou Z; Mallouri D; Constantinou V; Gavriilaki E; Smias C; Yannaki E; Kaloyannidis P; Papaioannou G; Stavroyianni N; Syrigou A; Sotiropoulos D; Fylaktou A; Tsompanakou A; Saloum R; Anagnostopoulos A
    Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):658-666. PubMed ID: 28716402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No indication of increased infection rates using low-dose alemtuzumab instead of anti-thymocyte globulin as graft-versus-host disease prophylaxis before allogeneic stem cell transplantation.
    Neumann T; Schneidewind L; Thiele T; Pink D; Schulze M; Schmidt C; Krüger W
    Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29178248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.